[go: up one dir, main page]

NL301233I2 - spesolimab - Google Patents

spesolimab

Info

Publication number
NL301233I2
NL301233I2 NL301233C NL301233C NL301233I2 NL 301233 I2 NL301233 I2 NL 301233I2 NL 301233 C NL301233 C NL 301233C NL 301233 C NL301233 C NL 301233C NL 301233 I2 NL301233 I2 NL 301233I2
Authority
NL
Netherlands
Prior art keywords
spesolimab
Prior art date
Application number
NL301233C
Other languages
English (en)
Other versions
NL301233I1 (nl
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47215803&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NL301233(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of NL301233I1 publication Critical patent/NL301233I1/nl
Publication of NL301233I2 publication Critical patent/NL301233I2/nl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
    • G01N2333/7155—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/20—Dermatological disorders
    • G01N2800/205—Scaling palpular diseases, e.g. psoriasis, pytiriasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Dermatology (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NL301233C 2011-11-16 2023-05-31 spesolimab NL301233I2 (nl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161560554P 2011-11-16 2011-11-16
US201261644111P 2012-05-08 2012-05-08
US201261713713P 2012-10-15 2012-10-15
PCT/US2012/064933 WO2013074569A1 (en) 2011-11-16 2012-11-14 Anti il-36r antibodies

Publications (2)

Publication Number Publication Date
NL301233I1 NL301233I1 (nl) 2023-06-07
NL301233I2 true NL301233I2 (nl) 2023-09-13

Family

ID=47215803

Family Applications (1)

Application Number Title Priority Date Filing Date
NL301233C NL301233I2 (nl) 2011-11-16 2023-05-31 spesolimab

Country Status (41)

Country Link
US (4) US9023995B2 (nl)
EP (2) EP2780373B1 (nl)
JP (3) JP6289375B2 (nl)
KR (3) KR102038310B1 (nl)
CN (5) CN107007833B (nl)
AP (1) AP2014007571A0 (nl)
AR (1) AR089178A1 (nl)
AU (1) AU2012339734B2 (nl)
BR (1) BR112014011594B1 (nl)
CA (1) CA2852994C (nl)
CL (1) CL2014001123A1 (nl)
CO (1) CO7020871A2 (nl)
CY (2) CY1122278T1 (nl)
DK (1) DK2780373T3 (nl)
EA (1) EA031948B1 (nl)
EC (1) ECSP14004976A (nl)
ES (1) ES2755732T3 (nl)
FI (2) FI3536710T3 (nl)
FR (1) FR23C1023I2 (nl)
GE (1) GEP20186816B (nl)
HR (1) HRP20191835T1 (nl)
HU (2) HUE047437T2 (nl)
IL (2) IL232100B (nl)
LT (3) LT3536710T (nl)
LU (1) LUC00308I2 (nl)
MX (1) MX347164B (nl)
MY (1) MY195289A (nl)
NL (1) NL301233I2 (nl)
NO (2) NO2023024I1 (nl)
PE (1) PE20142041A1 (nl)
PH (1) PH12014501108B1 (nl)
PL (1) PL2780373T3 (nl)
PT (1) PT2780373T (nl)
RS (1) RS59248B1 (nl)
SG (1) SG11201402283PA (nl)
SI (1) SI2780373T1 (nl)
TW (1) TWI573804B (nl)
UA (1) UA115540C2 (nl)
UY (1) UY34456A (nl)
WO (1) WO2013074569A1 (nl)
ZA (1) ZA201402491B (nl)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE053720T2 (hu) 2011-01-14 2021-07-28 Univ California ROR-1 fehérje elleni terápiás antitestek és eljárások alkalmazásukra
DK2780373T3 (da) 2011-11-16 2019-11-04 Boehringer Ingelheim Int Anti-IL-36R-antistoffer
PE20190658A1 (es) 2012-02-24 2019-05-08 Abbvie Stemcentrx Llc Moduladores y metodos de empleo novedosos
RS59853B1 (sr) * 2014-03-14 2020-02-28 Novartis Ag Molekuli anti-lag-3 antitela i njihove upotrebe
RU2582569C2 (ru) * 2014-07-24 2016-04-27 Федеральное государственное унитарное предприятие "Государственный научно-исследовательский институт особо чистых биопрепаратов" Федерального медико-биологического агентства Днк, кодирующая полноразмерный антагонист рецептора интерлейкина-36 человека, днк, кодирующая полноразмерный антагонист рецептора интерлейкина-36 человека с с-концевым полигистидиновым тагом, плазмидный экспрессионный вектор (варианты), штамм бактерий escherichia coli bl21 star[de3] (рет-il36raf), - продуцент полноразмерного рецепторного антагониста интерлейкина-36 и штамм бактерий escherichia coli bl21 star[de3] (pet-il36raf-his), - продуцент полноразмерного рецепторного антагониста интерлейкина-36 с с-концевым полигистидиновым тагом
FI3277321T3 (fi) 2015-04-01 2024-10-31 Anaptysbio Inc T-soluimmunoglobuliinia ja musiiniproteiini 3:a (tim-3) vastaan suunnattuja vasta-aineita
PL3283110T3 (pl) * 2015-04-15 2022-06-27 Anaptysbio, Inc. Przeciwciała skierowane przeciwko receptorowi interleukiny 36 (il-36r)
EP3307772B1 (en) * 2015-06-12 2020-09-09 Ludwig Institute For Cancer Research Limited Tgf-beta 3 specific antibodies and methods and uses thereof
JP6654773B2 (ja) * 2015-12-25 2020-02-26 国立大学法人名古屋大学 インターロイキン３６受容体アンタゴニスト欠損症の治療薬
CN110062885A (zh) 2016-11-01 2019-07-26 安奈普泰斯生物有限公司 针对t细胞免疫球蛋白和粘蛋白3（tim-3）的抗体
MA47206A (fr) 2017-01-09 2019-11-13 Tesaro Inc Méthodes de traitement du cancer au moyen d'anticorps anti-tim-3
JP2020512344A (ja) * 2017-03-27 2020-04-23 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗ｉｌ−３６ｒ抗体併用治療
US11207294B2 (en) * 2018-01-08 2021-12-28 Chemocentryx, Inc. Methods of treating generalized pustular psoriasis with an antagonist of CCR6 or CXCR2
MX2020009544A (es) * 2018-03-14 2020-10-05 Boehringer Ingelheim Int Uso de anticuerpos anti-il-36r para el tratamiento de la psoriasis pustulosa generalizada.
WO2019177883A2 (en) * 2018-03-14 2019-09-19 Boehringer Ingelheim International Gmbh Use of anti-il-36r antibodies for treatment of inflammatory bowel disease
US11589562B2 (en) * 2018-07-16 2023-02-28 Regeneran Pharmaceuticals, Inc. Mouse model of DITRA disease and uses thereof
EP3823989A2 (en) * 2018-07-16 2021-05-26 Regeneron Pharmaceuticals, Inc. Anti-il36r antibodies
CN112638946A (zh) 2018-08-16 2021-04-09 坎塔吉亚有限责任公司 抗il1rap抗体组合物
US20210380675A1 (en) * 2018-09-28 2021-12-09 Kyowa Kirin Co., Ltd. Il-36 antibodies and uses thereof
US11884719B2 (en) * 2018-12-21 2024-01-30 23Andme, Inc. Anti-IL-36 antibodies and methods of use thereof
JP2022515480A (ja) 2018-12-27 2022-02-18 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 掌蹠膿疱症の処置のための抗ｉｌ－３６ｒ抗体
BR112021016198A2 (pt) 2019-03-08 2021-11-03 Boehringer Ingelheim Int Formulações de anticorpo anti-il-36r
WO2021112196A1 (ja) * 2019-12-05 2021-06-10 学校法人東京薬科大学 筋組織の減少を抑制するための組成物
AR120913A1 (es) * 2019-12-27 2022-03-30 Teijin Pharma Ltd Anticuerpo que inhibe específicamente la señalización de il-36r
EP4153233A1 (en) 2020-05-19 2023-03-29 Boehringer Ingelheim International GmbH Anti-il-36r antibodies for the treatment of atopic dermatitis
JP2023534955A (ja) 2020-07-17 2023-08-15 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 好中球性皮膚症の処置のための抗ｉｌ－３６ｒ抗体
CN116406295A (zh) * 2020-07-30 2023-07-07 安奈普泰斯生物有限公司 针对鱼鳞病的抗白介素36受体（il-36r）疗法
WO2022026829A1 (en) 2020-07-30 2022-02-03 Anaptysbio, Inc. Anti-interleukin 36 receptor (il-36r) therapy for skin toxicity
CN116406290A (zh) 2020-09-30 2023-07-07 勃林格殷格翰国际有限公司 用于治疗慢性炎症性疼痛的抗il-36r抗体
CN112094349B (zh) * 2020-11-04 2021-02-09 上海华奥泰生物药业股份有限公司 靶向于白介素36r的抗体及其制备方法和应用
CN116685605A (zh) 2020-12-17 2023-09-01 上海华奥泰生物药业股份有限公司 靶向il-17a和il-36r的双特异性抗体及其应用
WO2022150642A1 (en) 2021-01-08 2022-07-14 Anaptysbio, Inc. Anti-interleukin 36 receptor (il-36r) therapy for hidradenitis suppurativa
WO2022150644A1 (en) 2021-01-08 2022-07-14 Anaptysbio, Inc. Anti-interleukin 36 receptor (il-36r) therapy for acne
WO2022166977A1 (zh) * 2021-02-08 2022-08-11 上海普铭生物科技有限公司 抗人il-36r抗体及其应用
KR20230154455A (ko) 2021-03-04 2023-11-08 베링거 인겔하임 인터내셔날 게엠베하 Gpp의 치료를 위한 방법
EP4305207A2 (en) 2021-03-12 2024-01-17 Boehringer Ingelheim International GmbH Biomarkers associated with anti-il-36r antibody treatment in generalized pustular psoriasis
CA3218684A1 (en) * 2021-05-03 2022-11-10 Boehringer Ingelheim International Gmbh Method for producing spesolimab
MX2023015283A (es) * 2021-06-18 2024-01-22 Chia Tai Tianqing Pharmaceutical Group Co Ltd Anticuerpo anti-il-36r y uso del mismo.
EP4370550A1 (en) 2021-07-12 2024-05-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of il-36 inhibitors for the treatment of netherton syndrome
WO2023019232A1 (en) 2021-08-13 2023-02-16 Boehringer Ingelheim International Gmbh Anti-il-36r antibodies for the treatment of a fibrotic condition
CN118302824A (zh) 2021-09-28 2024-07-05 柏林格英格翰国际有限公司 用于评估具有可见皮肤表现的嗜中性皮肤病的严重性的系统和方法
CN118355027A (zh) 2021-10-28 2024-07-16 艾伯维公司 抗淀粉样蛋白β抗体及其使用方法
TW202323293A (zh) * 2021-10-29 2023-06-16 新加坡商創響私人有限公司 新型抗ｉｌ－３６ｒ抗體
CN115724975A (zh) * 2022-10-20 2023-03-03 江苏荃信生物医药股份有限公司 抗人白介素36受体单克隆抗体及其应用
CN116574189A (zh) 2023-01-30 2023-08-11 北京智仁美博生物科技有限公司 针对人il-36r和/或人il-1r3的多种抗体及其用途
KR20250153801A (ko) 2023-02-21 2025-10-27 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 Il-36r 결합 단백질 및 이의 의학적 용도
KR20250155059A (ko) 2023-03-09 2025-10-29 베링거 인겔하임 인터내셔날 게엠베하 화농성 한선염(hs)의 치료를 위한 항-il-36r 항체의 용도
US20240409646A1 (en) 2023-06-09 2024-12-12 Boehringer Ingelheim International Gmbh Methods for the treatment and prevention of gpp

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4318980A (en) 1978-04-10 1982-03-09 Miles Laboratories, Inc. Heterogenous specific binding assay employing a cycling reactant as label
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
WO1981001145A1 (en) 1979-10-18 1981-04-30 Univ Illinois Hydrolytic enzyme-activatible pro-drugs
US4419446A (en) 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
GB8705477D0 (en) 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
WO1990003430A1 (en) 1988-09-23 1990-04-05 Cetus Corporation Cell culture medium for enhanced cell growth, culture longevity and product expression
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
DE122004000008I1 (de) 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
DE69315847T2 (de) 1992-08-21 1998-06-25 Genentech Inc Verfahren zur behandlung einer durch lfa-1 vermittelten störung
PL174494B1 (pl) 1992-11-13 1998-08-31 Idec Pharma Corp Kompozycja farmaceutyczna do leczenia chłoniaka z limfocytów B i sposób wytwarzania kompozycji farmaceutycznej do leczenia chłoniaka z limfocytów B
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US5888809A (en) 1997-05-01 1999-03-30 Icos Corporation Hamster EF-1α transcriptional regulatory DNA
US6416973B1 (en) 1997-08-01 2002-07-09 Schering Corporation Nucleic acids encoding mammalian cell membrane protein MDL-1
EP1798286B1 (en) 1997-08-01 2011-09-07 Schering Corporation Mammalian cell membrane proteins and related reagents
EP2857516B1 (en) * 2000-04-11 2017-06-14 Genentech, Inc. Multivalent antibodies and uses therefor
EP1627927A3 (en) * 2001-03-01 2006-06-07 Epigenomics AG Methods, systems and computer program products for determining the biological effect and/or activity of drugs, chemical substances and/or pharmaceutical compositions based on their effect on the methylation status of the DNA
EP1556403A4 (en) * 2002-10-03 2006-06-28 Large Scale Biology Corp ENGINEERING MULTIMERIC PROTEINS
RU2515108C2 (ru) * 2005-08-19 2014-05-10 Эббви Инк Иммуноглобулин с двойными вариабельными доменами и его применения
US20070041905A1 (en) 2005-08-19 2007-02-22 Hoffman Rebecca S Method of treating depression using a TNF-alpha antibody
US7612181B2 (en) * 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
MX341064B (es) * 2006-09-08 2016-08-05 Amgen Inc * Variantes de la familia il-1.
JP2010526066A (ja) 2007-04-23 2010-07-29 シェーリング コーポレイション 抗ｍｄｌ−１抗体
AU2008270710A1 (en) 2007-06-29 2009-01-08 Merck Sharp & Dohme Corp. MDL-1 uses
US20110159011A1 (en) 2008-08-28 2011-06-30 Wyeth Llc Uses of il-22, il-17, and il-1 family cytokines in autoimmune diseases
DK2780373T3 (da) 2011-11-16 2019-11-04 Boehringer Ingelheim Int Anti-IL-36R-antistoffer
PL3283110T3 (pl) 2015-04-15 2022-06-27 Anaptysbio, Inc. Przeciwciała skierowane przeciwko receptorowi interleukiny 36 (il-36r)

Also Published As

Publication number Publication date
CN107007833A (zh) 2017-08-04
EA031948B1 (ru) 2019-03-29
SG11201402283PA (en) 2014-06-27
TWI573804B (zh) 2017-03-11
NL301233I1 (nl) 2023-06-07
PH12014501108A1 (en) 2014-08-04
CL2014001123A1 (es) 2015-01-23
JP2018093885A (ja) 2018-06-21
GEP20186816B (en) 2018-02-12
NZ623425A (en) 2015-12-24
IL272035A (en) 2020-02-27
HUS2300021I1 (hu) 2023-07-28
CN112812183A (zh) 2021-05-18
FI3536710T3 (fi) 2026-01-14
EP3536710A1 (en) 2019-09-11
CA2852994C (en) 2023-02-14
AU2012339734A1 (en) 2014-04-24
BR112014011594A2 (pt) 2017-07-04
CY1122278T1 (el) 2020-11-25
RS59248B1 (sr) 2019-10-31
PT2780373T (pt) 2019-11-27
CY2023014I1 (el) 2023-11-15
US20200231684A1 (en) 2020-07-23
CN104080808B (zh) 2016-11-16
KR20140101738A (ko) 2014-08-20
US20240409648A1 (en) 2024-12-12
UY34456A (es) 2013-05-31
AP2014007571A0 (en) 2014-04-30
JP6289375B2 (ja) 2018-03-07
LTC2780373I2 (nl) 2024-11-11
US9023995B2 (en) 2015-05-05
CN112812183B (zh) 2024-06-11
AU2012339734B2 (en) 2017-02-16
EA201400579A1 (ru) 2014-10-30
ZA201402491B (en) 2021-09-29
EP3536710B1 (en) 2025-10-29
CO7020871A2 (es) 2014-08-11
IL232100B (en) 2020-04-30
JP2020156506A (ja) 2020-10-01
CY2023014I2 (el) 2023-11-15
US20150203584A1 (en) 2015-07-23
WO2013074569A1 (en) 2013-05-23
DK2780373T3 (da) 2019-11-04
ECSP14004976A (es) 2015-11-30
US20170298135A9 (en) 2017-10-19
EP2780373A1 (en) 2014-09-24
LT3536710T (lt) 2026-01-26
EP2780373B1 (en) 2019-08-21
LUC00308I2 (nl) 2025-09-22
CN107007833B (zh) 2020-12-11
HRP20191835T1 (hr) 2019-12-27
KR20190122877A (ko) 2019-10-30
AR089178A1 (es) 2014-08-06
FR23C1023I2 (fr) 2024-03-29
SI2780373T1 (sl) 2019-12-31
MX2014005759A (es) 2014-09-08
FR23C1023I1 (fr) 2023-07-21
JP2015500633A (ja) 2015-01-08
MX347164B (es) 2017-04-18
HUE047437T2 (hu) 2020-04-28
IL232100A0 (en) 2014-05-28
CA2852994A1 (en) 2013-05-23
ES2755732T3 (es) 2020-04-23
CN118496365A (zh) 2024-08-16
NO2023024I1 (no) 2023-05-30
FIC20230020I1 (fi) 2023-06-01
LT2780373T (lt) 2019-09-25
MY195289A (en) 2023-01-12
KR102038310B1 (ko) 2019-11-01
PE20142041A1 (es) 2014-12-18
KR20200110476A (ko) 2020-09-23
CN118515766A (zh) 2024-08-20
JP6719490B2 (ja) 2020-07-08
TW201333037A (zh) 2013-08-16
UA115540C2 (uk) 2017-11-27
US10550189B2 (en) 2020-02-04
BR112014011594B1 (pt) 2021-11-09
PH12014501108B1 (en) 2014-08-04
PL2780373T3 (pl) 2020-03-31
CN104080808A (zh) 2014-10-01
LTPA2023518I1 (nl) 2023-06-12
NO2025001I1 (no) 2025-01-03
KR102159109B1 (ko) 2020-09-23
US20130236471A1 (en) 2013-09-12

Similar Documents

Publication Publication Date Title
FIC20230020I1 (fi) Spesolimabi
DK2744810T4 (da) Tenofovir-alafenamid-hemifumarat
EP2715659A4 (en) ABOUT FEED
DK2769050T3 (da) Propsensor
DE102011100082A8 (de) Traygreifvorrichtung
EP2752374A4 (en) gooseneck
EP2795884A4 (en) Audio conferencing
BR112014000879A2 (pt) deflegmador
DK3272861T3 (da) Alpha-galactosidase-sammensætninger
EP2701512A4 (en) Aldosterone synthase inhibitors
CO6960543A2 (es) 2-tiopirimidinonas
EP2786752A4 (en) Ropinirole-containing adhesive patch
EP2723481A4 (en) FLOW COMPENSATOR
DK3141251T3 (da) Koloskopi - forberedelse
EP2708561A4 (en) BIO-PIN
EP2762923A4 (en) RADIATION MEASURING DEVICE
EP2738148A4 (en) RECIPROCAL LOCKING BLOCK
DE112011104936A5 (de) Stanzstauchniet
EP2760803A4 (en) Geopolymer product
EP2771685A4 (en) BIOMARKERS OF CANCER
DE112012000958A5 (de) Handsäge
EP2788163A4 (en) POST-MOLDING SYSTEM
EP2729467A4 (en) CRYPTATE COMPOUNDS
EP2698098A4 (en) campimeter
DK2476953T3 (da) Fluidbedkedel